SRR8942982
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.280
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.280
- IL6_JAK_STAT3_SIGNALING+0.150
- ANGIOGENESIS+0.140
- KRAS_SIGNALING_UP+0.120
- KRAS_SIGNALING_DN+0.100
- HEDGEHOG_SIGNALING+0.090
- MYOGENESIS+0.080
- COAGULATION+0.040
- INFLAMMATORY_RESPONSE+0.020
Top 10 suppressed
- P53_PATHWAY-0.420
- MYC_TARGETS_V2-0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.410
- MYC_TARGETS_V1-0.400
- OXIDATIVE_PHOSPHORYLATION-0.370
- ESTROGEN_RESPONSE_EARLY-0.340
- ESTROGEN_RESPONSE_LATE-0.340
- HYPOXIA-0.340
- ADIPOGENESIS-0.330
- TGF_BETA_SIGNALING-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0278634b-4a08-48df-ad10-35da36e56b19 | — | — | 0.861 |
| 2 | TCGA-91-A4BC-01A-11R-A24H-07 | — | cohortA3 | 0.854 |
| 3 | MDT-AP-1143 | Med | Medulloblastoma | 0.853 |
| 4 | SRR12202442 | — | — | 0.848 |
| 5 | SRR662342 | GTEX | — | 0.846 |
| 6 | SRR33346962 | — | — | 0.845 |
| 7 | MNG1003 | — | — | 0.845 |
| 8 | MNG1217 | — | — | 0.844 |
| 9 | MNG1135 | — | — | 0.843 |
| 10 | SRR1485167 | GTEX | — | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |
| COAGULATION | 0.040 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.020 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.010 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |